When prescribing tacrolimus (Protopic) to treat atopic dermatitis patients should be informed that:

A. Tacrolimus is the most effective if it is used continuously for 4 to 6 months: Tacrolimus is recommended for short-term or intermittent use in the management of atopic dermatitis, particularly when topical corticosteroids are ineffective or unsuitable for sensitive areas such as the face or skin folds. Continuous long-term use for several months is not advised. B. Tacrolimus should be spread generously over the affected area: Tacrolimus ointment should be applied as a thin layer to the affected skin areas rather than being spread generously. Using excessive amounts does not increase therapeutic benefit and may increase local adverse effects such as burning, stinging, or irritation. Appropriate dosing helps reduce systemic exposure. C. The FDA has issued a Black Box warning about the use of tacrolimus and the development of cancer in animals and humans: Tacrolimus is a topical calcineurin inhibitor that suppresses T-cell activation and decreases inflammatory cytokine release. Systemic calcineurin inhibitors have been associated with malignancies and animal studies suggested potential cancer risk, the FDA issued a Black Box warning regarding possible increased risk of lymphoma and skin cancer. D. The FDA recommends patients be screened for cancer before prescribing tacrolimus: Routine cancer screening prior to initiating topical tacrolimus therapy is not recommended by the FDA. The Black Box warning emphasizes cautious use, limiting prolonged exposure, and avoiding unnecessary immunosuppression rather than requiring formal malignancy screening.